Get notified of page updates
Education > XRAY > Breast Cancer

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Breast Cancer

51 through 60 of 251

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Frequency of inherited mutations linked to breast cancer are similar in Black and white women

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Non-Hispanic Black and white women with breast cancer

The CARRIERS study looked at the rate of inherited mutations in women with and without breast cancer. In an extension of the CARRIERS study, researchers found no difference in the frequency of inherited mutations in breast cancer genes among Black and white women with breast cancer. A few individual genes differed in frequency: BRCA2 and PALB2 mutations were seen more often in Black women, while CHEK2 mutations were seen less often. Researchers concluded that race should not be used to determine who is referred for genetic testing. (posted 8/13/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with early-stage HER2-negative breast cancer and an inherited BRCA mutation

The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

View Related Clinical Trials

Update : Breast cancer disparities in Black Americans

Relevance: Medium-High

Strength of Science: High

View Related Clinical Trials

Most relevant for: Black women in the US

The American Association for Cancer Research (AACR) released a 2020 report about cancer disparities among racial and ethnic groups in the United States. In this review, we highlight findings on the burden of breast cancer in Black women. (posted 8/5/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Cancer risks of people with inherited PALB2 mutations

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: people with inherited PALB2 mutations

In the largest study of people with inherited PALB2 mutations to date, the gene was linked to increased lifetime risk of breast cancer in women and men, ovarian and pancreatic cancer but not prostate or colorectal cancer. (posted 7/1/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Women can have safe pregnancies after breast cancer treatment

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women who have had breast cancer who are considering pregnancy.

In a large analysis of all published studies to date, most women who become pregnant after breast cancer treatment had safe pregnancies, with no increase in their cancer recurrence risk. Infants of mothers treated for breast cancer were more likely to have low birth weight, preterm birth and small size at birth but there was no increase in birth defects. Breast cancer survivors who became pregnant had a similar risk of recurrence and survival as survivors who did not become pregnant. (posted 6/24/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Study : Birth control pills may offer long-term protection against endometrial and ovarian cancer

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: People concerned about endometrial, ovarian or breast cancer risk

A large study showed that birth control pills may protect against endometrial and ovarian cancers, even years after use was discontinued. (posted 6/1/21)

Este artículo está disponible en español.

Read More

Relevance: Medium

Research Timeline: Human Research

View Related Clinical Trials

Update : FDA allows testing of a vaccine designed to prevent breast cancer

Relevance: Medium

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Patients with non-metastatic triple-negative breast cancer at high risk of recurrence.

Scientists have been working for many years to develop a vaccine that will prevent breast cancer. The FDA recently announced that the first clinical trial to test a preventive breast cancer vaccine can begin. This vaccine is the result of over a decade of research in animals and human cells. While researchers will first test the vaccine in women who have breast cancer, they hope to use this vaccine in the future to prevent breast cancer.  (posted 5/25/21)

THIS INFORMATION HAS BEEN UPDATED on 10/12/2021: The clinical trial discussed in this XRAY review has begun recruiting participants.  Researchers hope to enroll 24 patients with non-metastatic triple-negative breast cancer. The trial is being conducted at the Cleveland Clinic in Cleveland, Ohio. More information on this trial can be found here.

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

Study : Expanded access to Medicaid coverage under the Affordable Care Act is linked to reduced cancer mortality

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

Most relevant for: People with breast, colorectal or lung cancer.

In 2014 the Affordable Care Act expanded Medicaid coverage. How did this affect healthcare for cancer patients? This study shows that deaths from breast, colorectal and lung cancer are lower in states that chose to expand Medicaid compared to states that did not. Early diagnosis was linked to lower death rates. This suggests that increased healthcare access may lead to earlier cancer detection and better outcomes, including lower mortality. (3/31/2021)

Este artículo está disponible en español.

Read More

Relevance: High

Research Timeline: Post Approval

Guideline : Expert guidelines on COVID-19 vaccines and timing of breast screening tests

Relevance: High

Research Timeline: Post Approval

Most relevant for: People considering screening mammography after getting a COVID-19 vaccine.

COVID-19 vaccines work by helping the immune system destroy the virus. Lymph nodes are an important part of the immune system. COVID-19 vaccines may cause temporary swelling in some lymph nodes, which may look suspicious on a mammogram.  The Society for Breast Imaging and other professional organizations have released recommendations for the timing of mammograms after COVID-19 vaccines.  (3/30/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Patient outcomes and experiences of going flat

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: Women considering mastectomy without breast reconstruction.

Some patients with early-stage breast cancer or those considering risk-reducing surgery may choose mastectomy without reconstruction. This is often referred to as “going flat.” The results of this study suggest that surgeons play a significant role in supporting a patient’s decision to go flat. (3/23/2021)

Este artículo está disponible en español.

Read More

This Portal Sponsored By:

Centers for Disease Control